loading
Takeda Pharmaceutical Co Adr stock is traded at $15.19, with a volume of 4.31M. It is up +1.40% in the last 24 hours and up +2.36% over the past month. Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$14.98
Open:
$15.28
24h Volume:
4.31M
Relative Volume:
2.51
Market Cap:
$47.98B
Revenue:
$30.25B
Net Income/Loss:
$1.37B
P/E Ratio:
35.68
EPS:
0.4257
Net Cash Flow:
$5.08B
1W Performance:
+0.33%
1M Performance:
+2.36%
6M Performance:
+6.67%
1Y Performance:
+12.27%
1-Day Range:
Value
$15.09
$15.37
1-Week Range:
Value
$14.75
$15.37
52-Week Range:
Value
$12.57
$15.37

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name
Name
Takeda Pharmaceutical Co Adr
Name
Phone
-
Name
Address
-
Name
Employee
49,281
Name
Twitter
@takedapharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
TAK's Discussions on Twitter

Compare TAK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.19 47.98B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.61 71.47B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.45 47.20B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
14.85 17.02B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
307.36 13.80B 2.76B 1.11B 898.10M 22.77

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-02-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-16-23 Upgrade BofA Securities Neutral → Buy
Jul-19-22 Upgrade Cowen Market Perform → Outperform
Oct-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-19-21 Downgrade JP Morgan Overweight → Neutral
Nov-01-19 Initiated Cowen Market Perform
Aug-15-19 Downgrade Daiwa Securities Outperform → Neutral
View All

Takeda Pharmaceutical Co Adr Stock (TAK) Latest News

pulisher
Apr 03, 2025

Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize

Apr 03, 2025
pulisher
Apr 03, 2025

Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView

Apr 03, 2025
pulisher
Apr 02, 2025

UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients - Benzinga

Apr 02, 2025
pulisher
Mar 31, 2025

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo Finance

Mar 31, 2025
pulisher
Mar 14, 2025

PD Stock on the Rise: A Promising Investment - The InvestChronicle

Mar 14, 2025
pulisher
Mar 14, 2025

TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Mar 14, 2025
pulisher
Mar 14, 2025

China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

Mar 14, 2025
pulisher
Mar 14, 2025

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets

Mar 14, 2025
pulisher
Mar 13, 2025

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha

Mar 13, 2025
pulisher
Mar 10, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Mar 10, 2025
pulisher
Mar 06, 2025

Charles Schwab Trying To Close In On Key Technical Measure - Inkl

Mar 06, 2025
pulisher
Mar 04, 2025

Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle

Mar 04, 2025
pulisher
Mar 04, 2025

Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily

Mar 04, 2025
pulisher
Feb 18, 2025

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN

Feb 18, 2025
pulisher
Feb 17, 2025

TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq

Feb 17, 2025
pulisher
Feb 15, 2025

Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Vyvanse Leaks: Beyond The Headlines - Truth or Fiction

Feb 15, 2025
pulisher
Feb 14, 2025

IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR

Feb 14, 2025
pulisher
Feb 13, 2025

IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR

Feb 13, 2025
pulisher
Feb 10, 2025

Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News

Feb 10, 2025
pulisher
Feb 07, 2025

Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

GFL Shares Experience Surge in Value - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News

Feb 07, 2025
pulisher
Feb 05, 2025

Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater

Feb 05, 2025
pulisher
Feb 03, 2025

Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily

Feb 03, 2025
pulisher
Jan 30, 2025

Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition - MSN

Jan 30, 2025
pulisher
Jan 27, 2025

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World - Dealbreaker

Jan 27, 2025
pulisher
Jan 21, 2025

Keros Therapeutics seals $200M deal with Takeda - Investing.com

Jan 21, 2025
pulisher
Jan 15, 2025

Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald

Jan 15, 2025
pulisher
Jan 14, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 14, 2025

Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic HLN
$10.45
price up icon 2.85%
drug_manufacturers_specialty_generic ZTS
$159.61
price down icon 2.38%
$14.85
price down icon 2.88%
$307.36
price down icon 1.57%
$102.88
price down icon 5.01%
Cap:     |  Volume (24h):